Your browser doesn't support javascript.
loading
The DNA Damage Response and Inflammation in Cancer.
Klapp, Vanessa; Álvarez-Abril, Beatriz; Leuzzi, Giuseppe; Kroemer, Guido; Ciccia, Alberto; Galluzzi, Lorenzo.
Afiliação
  • Klapp V; Department of Radiation Oncology, Weill Cornell Medical College, New York, New York.
  • Álvarez-Abril B; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Leuzzi G; Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Kroemer G; Department of Radiation Oncology, Weill Cornell Medical College, New York, New York.
  • Ciccia A; Department of Hematology and Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain.
  • Galluzzi L; Department of Genetics and Development, Columbia University Irving Medical Center, New York, New York.
Cancer Discov ; 13(7): 1521-1545, 2023 07 07.
Article em En | MEDLINE | ID: mdl-37026695
ABSTRACT
Genomic stability in normal cells is crucial to avoid oncogenesis. Accordingly, multiple components of the DNA damage response (DDR) operate as bona fide tumor suppressor proteins by preserving genomic stability, eliciting the demise of cells with unrepairable DNA lesions, and engaging cell-extrinsic oncosuppression via immunosurveillance. That said, DDR sig-naling can also favor tumor progression and resistance to therapy. Indeed, DDR signaling in cancer cells has been consistently linked to the inhibition of tumor-targeting immune responses. Here, we discuss the complex interactions between the DDR and inflammation in the context of oncogenesis, tumor progression, and response to therapy.

SIGNIFICANCE:

Accumulating preclinical and clinical evidence indicates that DDR is intimately connected to the emission of immunomodulatory signals by normal and malignant cells, as part of a cell-extrinsic program to preserve organismal homeostasis. DDR-driven inflammation, however, can have diametrically opposed effects on tumor-targeting immunity. Understanding the links between the DDR and inflammation in normal and malignant cells may unlock novel immunotherapeutic paradigms to treat cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dano ao DNA / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dano ao DNA / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article